Nomad Power Solutions, Inc.NMAD
Price (close)
$3.63
Market cap
$58.4M
P/E
—
Revenue (TTM)
—
Net income
-$8.7M
Dividend yield
—
1-year total return
-30.9%
Net margin
—
Revenue growth
—
Debt / equity
—
What Nomad Power Solutions, Inc. does.
Company is a clinical-stage biopharmaceutical and proton cancer therapy company focused on identifying new targets for cancer drug development
and developing and commercializing cancer therapies. The Company’s drug product pipeline is primarily focused on inhibitors of
protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Net income | -$3.3M | -$6.7M | -$6.3M | -$5.1M | -$3.6M | -$6.1M |
More on NMAD.
- Nomad Power Solutions, Inc. summary
- Nomad Power Solutions, Inc. financial statements
- Nomad Power Solutions, Inc. key metrics
- Nomad Power Solutions, Inc. health scores and style box
- Nomad Power Solutions, Inc. earnings
- Nomad Power Solutions, Inc. dividends
- Nomad Power Solutions, Inc. valuation
- Nomad Power Solutions, Inc. ownership and insiders
- Nomad Power Solutions, Inc. peers
Figures from Nomad Power Solutions, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.